Literature DB >> 22696639

Suboptimal provirus expression explains apparent nonrandom cell coinfection with HIV-1.

Christelle Brégnard1, Gregory Pacini, Olivier Danos, Stéphane Basmaciogullari.   

Abstract

Despite the ability of primate lentiviruses to prevent infected cells from being reinfected, cell coinfection has occurred in the past and has shaped virus evolution by promoting the biogenesis of heterozygous virions and recombination during reverse transcription. In vitro experiments have shown that cell coinfection with HIV is more frequent than would be expected if coinfection were a random process. A possible explanation for this bias is the heterogeneity of target cells and the preferred infection of a subpopulation. To address this question, we compared the frequency of double-positive cells measured following coincubation with green fluorescent protein (GFP) and DsRed HIV reporter viruses with that of stochastic coinfection calculated as the product of the frequencies of GFP- and DsRed-positive cells upon incubation with either reporter virus. Coinfection was more frequent than would be expected on the grounds of stochastic infection, due to the underestimation of single-infection frequencies, which mathematically decreased the calculated frequency. Indeed, when cells were incubated with either reporter virus, a fraction of the cells were scored as uninfected yet harbored a silent provirus that was reactivated upon coinfection through cross talk between viral elements. When such cross talk was avoided, experimental and calculated coinfection frequencies matched, indicating random coinfection. The proportion of infected cells harboring a silent provirus was estimated from coinfection experiments and was shown to be cell type dependent but independent of the virus entry route.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22696639      PMCID: PMC3421764          DOI: 10.1128/JVI.00831-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  59 in total

1.  Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors.

Authors:  R Zufferey; J E Donello; D Trono; T J Hope
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

2.  The viral protein Tat can inhibit the establishment of HIV-1 latency.

Authors:  Daniel A Donahue; Björn D Kuhl; Richard D Sloan; Mark A Wainberg
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

Review 3.  The multifactorial nature of HIV-1 latency.

Authors:  Kara Lassen; Yefei Han; Yan Zhou; Janet Siliciano; Robert F Siliciano
Journal:  Trends Mol Med       Date:  2004-11       Impact factor: 11.951

4.  The art gene product of human immunodeficiency virus is required for replication.

Authors:  E Terwilliger; R Burghoff; R Sia; J Sodroski; W Haseltine; C Rosen
Journal:  J Virol       Date:  1988-02       Impact factor: 5.103

5.  Mechanisms of nonrandom human immunodeficiency virus type 1 infection and double infection: preference in virus entry is important but is not the sole factor.

Authors:  Jianbo Chen; Que Dang; Derya Unutmaz; Vinay K Pathak; Frank Maldarelli; Douglas Powell; Wei-Shau Hu
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

6.  The Nef protein of human immunodeficiency virus establishes superinfection immunity by a dual strategy to downregulate cell-surface CCR5 and CD4.

Authors:  Nico Michel; Ina Allespach; Stephanie Venzke; Oliver T Fackler; Oliver T Keppler
Journal:  Curr Biol       Date:  2005-04-26       Impact factor: 10.834

7.  Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.

Authors:  L M Mansky; H M Temin
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

8.  Analysis in human immunodeficiency virus type 1 vectors of cis-acting sequences that affect gene transfer into human lymphocytes.

Authors:  C Parolin; T Dorfman; G Palú; H Göttlinger; J Sodroski
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

9.  A third-generation lentivirus vector with a conditional packaging system.

Authors:  T Dull; R Zufferey; M Kelly; R J Mandel; M Nguyen; D Trono; L Naldini
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

10.  Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery.

Authors:  R Zufferey; T Dull; R J Mandel; A Bukovsky; D Quiroz; L Naldini; D Trono
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

View more
  6 in total

1.  Latent HIV-1 can be reactivated by cellular superinfection in a Tat-dependent manner, which can lead to the emergence of multidrug-resistant recombinant viruses.

Authors:  Daniel A Donahue; Sophie M Bastarache; Richard D Sloan; Mark A Wainberg
Journal:  J Virol       Date:  2013-06-26       Impact factor: 5.103

2.  Synaptic transmission may provide an evolutionary benefit to HIV through modulation of latency.

Authors:  Cesar Vargas-Garcia; Ryan Zurakowski; Abhyudai Singh
Journal:  J Theor Biol       Date:  2018-07-23       Impact factor: 2.691

Review 3.  Retroviral vectors for analysis of viral mutagenesis and recombination.

Authors:  Jonathan M O Rawson; Louis M Mansky
Journal:  Viruses       Date:  2014-09-24       Impact factor: 5.048

4.  Pyroptosis, superinfection, and the maintenance of the latent reservoir in HIV-1 infection.

Authors:  Dominik Wodarz; David N Levy
Journal:  Sci Rep       Date:  2017-06-19       Impact factor: 4.379

5.  Number of infection events per cell during HIV-1 cell-free infection.

Authors:  Yusuke Ito; Azaria Remion; Alexandra Tauzin; Keisuke Ejima; Shinji Nakaoka; Yoh Iwasa; Shingo Iwami; Fabrizio Mammano
Journal:  Sci Rep       Date:  2017-07-26       Impact factor: 4.379

6.  Central memory CD4+ T cells are preferential targets of double infection by HIV-1.

Authors:  Aiman A Haqqani; Samantha L Marek; Jagadish Kumar; Miles Davenport; Heng Wang; John C Tilton
Journal:  Virol J       Date:  2015-11-11       Impact factor: 4.099

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.